Shield receives CHMP positive opinion for Feraccru to treat iron deficiency in adults
This recommendation will now go forward to the European Commission for ratification and implementation over the next two to three months. Feraccru, the Company’s lead asset, is currently
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.